Endocrine Abstracts

Background: Adrenocortical carcinoma (ACC) is a rare but devastating malignancy (5-year survival 18–57%), with limited treatment options. Currently, mitotane is the first-line medical treatment for metastatic ACC and is used in the adjuvant setting after surgery to prevent recurrence. Mitotane is an adrenolytic drug that is thought to act by disruption of mitochondria with subsequent activation of apoptosis. However, mitotane treatment comes with many drawbacks, such as s...